

## arGEN-X to Present at Wedbush PacGrow Healthcare Conference

**Breda, the Netherlands / Ghent, Belgium, 6 August 2015** - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present a corporate update at the Wedbush PacGrow Healthcare Conference in New York City (NY, USA) on Wednesday, August 12, 2015 at 1:20pm ET.

### About arGEN-X

arGEN-X combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for longer duration of effect and greater efficacy. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey.

arGEN-X is listed on the Euronext Brussels exchange under the symbol ARGX.

[www.arGEN-X.com](http://www.arGEN-X.com)

*SIMPLE Antibody(TM), NHance® and ABDEG(TM) are trademarks of arGEN-X NV  
POTELLIGENT® is a trademark of BioWa Inc.*

### For further information, please contact:

Joke Comijn, Corporate Communications Manager  
+32 (0)477 77 29 44  
+32 (0)9 243 40 70  
[info@arGEN-X.com](mailto:info@arGEN-X.com)

Mark Swallow/David Dible  
Citigate Dewe Rogerson  
+44 207 282 2948  
[arGEN-X@citigatedr.co.uk](mailto:arGEN-X@citigatedr.co.uk)

Beth DelGiacco (US IR)  
Stern Investor Relations  
+1 212 362 1200  
[beth@sternir.com](mailto:beth@sternir.com)